> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Verrica Pharma NDA Planned for Skin Disease Drug
- URL: https://www.fdaweb.com/verrica-pharma-nda-planned-for-skin-disease-drug/
- Published: 2019-01-04T12:00:00.000Z
- Updated: 2026-09-15T00:52:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143090

Verrica Pharmaceuticals says it is planning an NDA submission in the second half of the year for VP-102 for treating molluscum contagiosum, a highly contagious skin disease affecting primarily children. The submission will be based on just-reported data from the company’s Phase 3 CAMP-1 and CAMP-2 pivotal trials with VP-102\. “In each trial, VP-102 exhibited a clinically and statistically significant proportion of subjects demonstrating complete clearance of all treatable molluscum lesions versus placebo,” the company says. “VP-102 was well-tolerated in both trials, with no serious adverse events reported in VP-102 treated subjects.”

VP-102 is described by the company as a proprietary topical drug-device combination therapy containing a novel topical solution of 0.7% cantharidin for treating molluscum and verruca vulgaris (common warts). Verrica is also currently evaluating and prioritizing other potential indications for VP-102 and the company’s proprietary cantharidin topical solution.